BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Novo  Nordisk  A/S  submitted  on  2  June  2000  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Prandin,  through  the  centralised 
procedure. 
This submission concerns an abridged application for three strengths of Prandin tablets 0.5 mg, 1 mg 
and  2  mg.  This  application  has  been  in  accordance  with  Chapter  II,  Article  4.8.a.  (i)  of  Council 
Directive  65/65/EEC  of  26  January  1995,  as  amended.  The  Marketing  Authorisation  Holder  of 
NovoNorm tablets, Novo Nordisk A/S, Denmark, consented to the pharmacological, toxicological and 
clinial data contained in the original file of NoveNorm to be used in the purpose of this application. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr S. Bronswijk 
Co-Rapporteur: 
Pharm J. Genoux-Hames 
Licensing status: 
This  product  was  not  licensed  in  the  European  Union  at  the  time  of  submission  of  the  application. 
However,  an  essentially  similar  product,  under  the  name  of  NovoNorm,  was  authorised  in  the  EU 
through the centralised procedure on 17 August 1998. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
The procedure started on 20 June 2000. 
The  Rapporteur  and  Co-Rapporteur's  joint  assessment  report  was  circulated  to  all  CPMP 
Members on 14 August 2000.  
During  the  meeting  on  19-21  September  2000  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee  issued  a  positive  Opinion  for 
granting a Marketing Authorisation to Prandin on 21 September 2000. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 29 January 2001. 
1/1 
EMEA 2004 
 
 
